Robert Gabbay, Md, Phd: The Debate About Sglt-2 Inhibitors And Glp-1 Receptor Agonists

Robert Gabbay, MD, PhD: The Debate About SGLT-2 Inhibitors and GLP-1 Receptor Agonists

Dr Darren McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

Dr Robert Gabbay Explains Controversy Over Recent A1C Guidelines

Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

Peter Toth, MD: GLP-1 Agonists and SGLT-2 Inhibitors for Diabetes

SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Robert Gabbay, MD, PhD: Medication Adherence and Patient-Provider Communication

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

Endocrine Society

The Daily Debate - SGLT-2 Inhibitors and T1D

WebsEdgeMedicine

Dr Robert Gabbay Outlines the Importance of Collaborative Care for Patients With Diabetes

Using GLP-1 Agonists & SGLT-2 Inhibitors Together from the Cardiologist's Perspective (SGLT2 & GLP1)

Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?

Dr Robert Gabbay: New Therapy Options Makes It Easier to Manage Patients With Diabetes

GLP-1 Receptor Agonists and Cardiovascular Benefit

Dr Robert Gabbay Discusses Disseminating the Joslin Clinical Guidelines

Dr Robert Gabbay Describes Participation Levels in Diabetes Clinical Trials

Dr Robert Gabbay on Diabetes in the COVID-19 Era

Dr Robert A. Gabbay Highlights the Development of Joslin Diabetes Center’s Clinical Guidelines